On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

EnteroMedics, Inc. (ETRM) is Pulling its Weight in the Fight Against Obesity

EnteroMedics, Inc. (NASDAQ: ETRM) aims to make America leaner and fitter. The company, based in St. Paul, Minnesota, provides safe, reliable and effective products and therapies to treat obesity and metabolic disorders. Its signature technology, the vBloc® vagal blocking therapy delivered via the Maestro® Rechargeable System, is gaining increasing acceptance both domestically and abroad. vBloc® offers the overweight and the obese relief from those extra pounds that, all too often, trigger a variety of problematic medical conditions.

Overweight and obesity are global problems, but America appears to have taken the cake. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an agency of the U.S. Department of Health and Human Services, has published statistics that are quite alarming. ‘More than 2 in 3 adults are considered to be overweight or obese’ and ‘more than 1 in 3 adults are considered to be obese’.

Overweight is excess body weight due to too much muscle, bone, fat or water. Obesity is an excess amount of body fat. One measure of overweight and obesity is the Body Mass Index (BMI), which is a person’s weight (in kilograms) divided by the square of his or her height (in meters). Your weight is considered normal if the BMI is under 25. Anyone with a BMI over 25 and under 30 is considered overweight. If your BMI is 30 or over, you are obese.

Extra weight means extra stress for the vital organs. The liver, heart, kidneys and pancreas are all adversely affected by visceral fat, the internal fatty tissue that develops to enfold them. Unlike the benign deposits of fat that lie just beneath the skin, which shape our figures, visceral fat is highly toxic. ‘Visceral fat has been linked to metabolic disturbances and increased risk for cardiovascular disease and type 2 diabetes. In women, it is also associated with breast cancer and the need for gallbladder surgery’, according to this (http://nnw.fm/X3yMv) Harvard Medical School publication. The NIDDK lists the health risks of overweight and obesity as type 2 diabetes, heart disease, high blood pressure, nonalcoholic fatty liver disorders, osteoarthritis, stroke and cancers of the breast, colon, uterine lining and kidney.

Chronic cases of overweight and obesity are treated by surgery. American Society for Metabolic and Bariatric Surgery (ASMBS) figures, as reported by News Medical (http://nnw.fm/wqO9P), relate that ‘about 193,000 people had bariatric surgery in 2014… sleeve gastrectomy was… found to be the most common procedure, accounting for 51.7 percent of weight-loss operations, followed by gastric bypass (26.8%), gastric band (9.5%), and biliopancreatic diversion with duodenal switch (0.4%).’ These are all intensely intrusive procedures with many risks that may be hard to stomach. Sleeve gastrectomy, for example, is a procedure in which up to 80 percent of the stomach can be removed.

The vBloc® vagal blocking therapy from EnteroMedics, Inc. is, on the other hand, minimally invasive. It is implanted under the skin just outside the ribcage and involves limited scarring. Recovery time from surgery is short. Some patients reported having the surgery on Friday and going out to work the following Monday.

The vBloc® Therapy works to control sensations of hunger using a pacemaker-like device. A Briefing Document (http://nnw.fm/rgBZ4) on the FDA website indicates that when the therapy is used for 12 hours per day as prescribed, patients experienced an average excess weight loss of 28 percent over one year. This was 50 percent more weight loss than patients who did not receive vBloc®.

In June 2016, EnteroMedics announced a series of successful vBloc procedures at the Beltline Bariatric and Surgical Group in Atlanta, Georgia. And this week, it was disclosed that the European Patent Office had issued a Notice of Intention to Grant a European Patent covering safety features of the Company’s vBloc® Neurometabolic Therapy System. EnteroMedics, with its vBloc® Therapy, is beginning to look like a heavy hitter.

For more information, please visit www.vbloc.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217